Figure 1.

PTX, ACY-241 and A452 individually suppress the growth and viability of the AT-rich interaction domain 1A-null, p53-wild-type TOV-21G ovarian cancer cell line. (A and B) PTX (0, 0.1, 1, 3, 10, 30 and 100 nM), (C and D) ACY-241 (0, 0.1, 0.3, 1, 3, 10 and 30 µM) and (E and F) A452 (0, 0.1, 0.3, 1, 3, 10 and 30 µM) were used for treatment of TOV-21G cells for 24, 48 and 72 h at the respective concentrations. (A, C and E) Cell growth and (B, D and F) cell viability were measured using Cell Counting Kit-8 assays in 96-well plates. All three drugs inhibited the growth and decreased the viability of TOV-21G cells. Cell counts were estimated indirectly from a standard curve derived from absorbance of known cell numbers. The absorbance at each concentration was normalized to that of the negative control within the corresponding time interval. Data are presented as the mean ± SD (n=3). **P<0.01 and ***P<0.001 vs. the DMSO control (one-way ANOVA with Bonferroni's post hoc test; the significance levels apply to all samples under a line). PTX, paclitaxel.